Mirum Pharmaceuticals (MIRM) SVP Howe Sells $264K of Stock

Jolanda Howe, the Senior Vice President and Global Controller at Mirum Pharmaceuticals, Inc. (NasdaqGM: MIRM), executed a planned sale of company shares. On June 17, 2026, Howe sold 2,594 shares at an average price of $101.95, amounting to a total transaction value of approximately $264,458.

Mirum Pharmaceuticals, Inc. Stock Up 16.1%

Shares of Mirum Pharmaceuticals recently traded around $102.04. The company boasts a market capitalization of about $6.22 billion. Despite its promising pipeline, Mirum currently isn't profitable, reflected in its negative forward P/E ratio of -1166.17. The stock has shown some volatility, with a 52-week low of $47.89 and a high of $114.99. Its 50-day moving average stands at $98.44, and the 200-day moving average is $85.99. The company maintains a current ratio of 2.09 and a quick ratio of 1.90, although it has a relatively high debt-to-equity ratio of 133.52.

Recent Earnings

In its most recent financial report, Mirum Pharmaceuticals disclosed revenue of $569.6 million, marking a growth of 43.3%. However, the company reported a net margin of -140.24% and a return on equity of -335.82%, highlighting its ongoing challenges in achieving profitability. Investors will be looking for updates during its next earnings release scheduled for August 5, 2026.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company based in Foster City, California. It focuses on developing and commercializing therapies for rare and debilitating diseases. Its lead product, LIVMARLI, is approved for treating Alagille syndrome-related cholestatic pruritus. The company also markets Cholbam and Chenodal for specific liver and metabolic disorders. Mirum is actively engaged in research and development of additional treatments, including Volixibat and Brelovitug, and maintains collaborations with several pharmaceutical entities. Founded in 2018, the company is led by CEO Christopher Peetz and employs 418 people.

Bottom Line

Jolanda Howe's recent stock sale under a pre-arranged plan should be seen as part of routine insider activity. Investors in Mirum Pharmaceuticals keep a close watch on such transactions, along with the company's efforts to advance its pipeline of rare disease therapies. As always, it's important to remember that insider sales do not necessarily signal negative sentiment. The information here reflects past events and should not be interpreted as a current investment recommendation.